Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Medical Supplies Industry Analysis

UpdatedNov 14, 2025
DataAggregated Company Financials
Companies40
  • 7D1.8%
  • 3M1.1%
  • 1Y-24.7%
  • YTDn/a

In the last week, the Medical Supplies industry is up 1.8%, with Solventum up 5.4%. However, the industry is down 25% over the past year. Earnings are forecast to grow by 29% annually.

Industry Valuation and Performance

Has the U.S. Medical Supplies Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 18 Nov 2025US$69.0bUS$36.2b-US$208,713,600.0021x-330.5x1.9x
Thu, 16 Oct 2025US$66.3bUS$36.1b-US$1,348,148,630.0021.3x-49.2x1.8x
Sat, 13 Sep 2025US$68.1bUS$36.1b-US$1,395,631,837.0021.8x-48.8x1.9x
Mon, 11 Aug 2025US$66.7bUS$36.0b-US$1,418,409,228.0023.2x-47x1.9x
Wed, 09 Jul 2025US$76.1bUS$36.0b-US$853,313,948.3827.2x-89.2x2.1x
Fri, 06 Jun 2025US$72.8bUS$36.0b-US$853,314,114.6727.2x-85.3x2x
Sun, 04 May 2025US$76.3bUS$35.9b-US$686,648,534.0024.7x-111.1x2.1x
Tue, 01 Apr 2025US$78.4bUS$35.9b-US$625,773,350.0025.4x-125.3x2.2x
Thu, 27 Feb 2025US$84.9bUS$35.7bUS$153.7m22.9x552.3x2.4x
Sat, 25 Jan 2025US$91.3bUS$35.5bUS$709.3m28.7x128.7x2.6x
Mon, 23 Dec 2024US$87.2bUS$35.5bUS$1.2b32x75x2.5x
Wed, 20 Nov 2024US$92.6bUS$35.4bUS$1.1b35.4x82x2.6x
Fri, 18 Oct 2024US$98.8bUS$35.0bUS$1.6b36.1x60.8x2.8x
Sun, 15 Sep 2024US$99.7bUS$35.0bUS$1.6b40.7x60.8x2.8x
Tue, 13 Aug 2024US$90.9bUS$35.1bUS$1.6b40.2x56.6x2.6x
Thu, 11 Jul 2024US$87.4bUS$34.8bUS$2.1b41.6x41.5x2.5x
Sat, 08 Jun 2024US$92.5bUS$34.8bUS$2.1b40.6x43.9x2.7x
Mon, 06 May 2024US$92.0bUS$34.5bUS$2.2b41.8x42x2.7x
Wed, 03 Apr 2024US$97.0bUS$34.2bUS$2.1b42.1x47.1x2.8x
Fri, 01 Mar 2024US$83.8bUS$25.9bUS$564.1m41x148.6x3.2x
Sun, 28 Jan 2024US$80.5bUS$26.2bUS$280.6m40.1x286.9x3.1x
Tue, 26 Dec 2023US$83.7bUS$26.2bUS$242.3m39.2x345.4x3.2x
Thu, 23 Nov 2023US$74.3bUS$26.1bUS$223.4m41.4x332.4x2.8x
Sat, 21 Oct 2023US$78.8bUS$25.9b-US$705,469,291.0035.2x-111.7x3x
Mon, 18 Sep 2023US$88.7bUS$25.8b-US$702,385,029.0034.3x-126.3x3.4x
Wed, 16 Aug 2023US$95.5bUS$25.7b-US$689,294,124.0034.8x-138.6x3.7x
Fri, 14 Jul 2023US$100.0bUS$25.1b-US$585,997,456.0035.2x-170.6x4x
Sun, 11 Jun 2023US$91.6bUS$25.6b-US$571,795,238.0036.9x-160.3x3.6x
Tue, 09 May 2023US$94.7bUS$25.4b-US$556,771,859.0039.2x-170.1x3.7x
Thu, 06 Apr 2023US$94.0bUS$25.4b-US$331,245,554.0046.6x-283.7x3.7x
Sat, 04 Mar 2023US$94.7bUS$25.5b-US$462,953,803.0044x-204.5x3.7x
Mon, 30 Jan 2023US$89.5bUS$25.1b-US$38,373,185.0038.3x-2332.1x3.6x
Wed, 28 Dec 2022US$72.9bUS$23.9b-US$37,405,016.0032.8x-1948.8x3.1x
Fri, 25 Nov 2022US$77.1bUS$24.9bUS$153.0m34.1x504x3.1x
Price to Earnings Ratio

504x


Total Market Cap: US$77.1bTotal Earnings: US$153.0mTotal Revenue: US$24.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Medical Supplies Industry Price to Earnings3Y Average 9.6x202320242025
Current Industry PE
  • Investors are pessimistic on the American Health Care Supplies industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.8x is higher than the industry's current PS ratio of 1.9x.
Past Earnings Growth
  • Total earnings for the Health Care Supplies industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have grown 13% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does U.S. Medical Supplies compare with similar industries?

US Market-0.39%
Healthcare3.77%
Medical Equipment1.73%
Medical Supplies1.84%
Medical Equipment1.73%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOLV SolventumUS$76.196.1%
+US$763.2m		13.5%PE8.7x
HAE HaemoneticsUS$74.325.4%
+US$179.7m		-15.7%PE20.7x
COO Cooper CompaniesUS$71.350.9%
+US$125.2m		-28.3%PE34.8x
LNTH Lantheus HoldingsUS$52.503.6%
+US$120.0m		-31.1%PE20.8x
EMBC EmbectaUS$14.314.7%
+US$37.4m		-0.8%PE10x

Latest News

SOLV
US$76.19
Solventum
7D
6.1%
1Y
13.5%
SMTI
US$21.07
Sanara MedTech
7D
-25.2%
1Y
-40.4%

SMTI: Leadership Transition And Streamlined Operations Will Drive Profitability Expansion

Narrative Update on Sanara MedTech: Analyst Price Target Revision Analysts have lowered their price target for Sanara MedTech from $50.00 to $41.00, citing updated estimates for key valuation metrics and a moderation in projected revenue growth. What's in the News Sanara MedTech is discontinuing operations of Tissue Health Plus (THP) to improve operating efficiency and will reclassify THP as discontinued operations in financial statements.
TELA
US$1.14
TELA Bio
7D
-4.2%
1Y
-60.4%
BLCO
US$15.00
Bausch + Lomb
7D
-6.1%
1Y
-24.1%
UFPT
US$222.82
UFP Technologies
7D
-5.0%
1Y
-20.1%
MMSI
US$85.79
Merit Medical Systems
7D
-2.9%
1Y
-17.5%
HAE
US$74.32
Haemonetics
7D
5.4%
1Y
-15.7%

HAE: Upbeat Execution And Reset Guidance Should Drive Share Price Recovery

Haemonetics' analyst price target has been raised from $76.27 to $83.00, as analysts cite improved execution, strong segment performance, and a more optimistic sales outlook as key drivers for the upward revision. Analyst Commentary Following recent quarterly results and the revised price target, analysts have shared both optimistic highlights and points of caution regarding Haemonetics' outlook and valuation.
EMBC
US$14.31
Embecta
7D
4.7%
1Y
-0.8%
XRAY
US$10.39
DENTSPLY SIRONA
7D
-5.5%
1Y
-43.7%
ESTA
US$65.84
Establishment Labs Holdings
7D
-2.7%
1Y
74.3%

US$62.22 - That's What Analysts Think Establishment Labs Holdings Inc. (NASDAQ:ESTA) Is Worth After These Results

Nov 08
US$62.22 - That's What Analysts Think Establishment Labs Holdings Inc. (NASDAQ:ESTA) Is Worth After These Results
ALGN
US$132.61
Align Technology
7D
-4.1%
1Y
-42.3%

ALGN: Volume Upside and Margin Strength Will Drive a Positive Outlook

Analysts have increased their price target for Align Technology from $175.07 to $180.50, citing improved revenue growth prospects, a stronger profit margin outlook, and management's recent success in delivering volume upside despite concerns about seasonality. Analyst Commentary Recent analyst updates on Align Technology reflect a range of perspectives, highlighting both positive developments and ongoing concerns in the company's outlook.
ICUI
US$134.52
ICU Medical
7D
-3.4%
1Y
-20.9%
LNTH
US$52.50
Lantheus Holdings
7D
3.6%
1Y
-31.1%

LNTH: Future Pipeline Advances Will Drive Recovery As Market Uncertainty Fades

Lantheus Holdings' analyst price target has been reduced from $109 to a range between $63 and $84. This reflects a more cautious outlook as analysts cite continued uncertainty around Pylarify's market share and slower growth visibility in the near term.
NSPR
US$2.01
InspireMD
7D
19.6%
1Y
-22.4%
COO
US$71.35
Cooper Companies
7D
0.9%
1Y
-28.3%
NEOG
US$6.42
Neogen
7D
0.9%
1Y
-57.8%

NEOG: Rising Profit Margins And New Partnerships Will Drive Future Expansion

Narrative Update: Neogen Analyst Price Target Revised Analysts have slightly raised their price target for Neogen, citing improvements in expected profit margins and a modest decline in projected future valuation multiples. This has resulted in a new estimated fair value of $8.17 per share.